secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vericel Corp (VCEL)
CIK:        0000887359
Form:       8-K
Filed at:   2024-08-01T23:59:59+00:00
Accession:  0001628280-24-033894
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vericel Q2 revenue rises 15% to $52.7M; MACI up 21%; raises FY2024 margin guidance to 71%
--------------------------------------------------------------------------------

- MACI net revenue $44.1M (+21% YoY); NexoBrid revenue $0.8M (+76% QoQ); Burn Care franchise total $8.5M.
- Gross margin 70% (up 430bps); adjusted EBITDA $6.3M (+42%), margin 12% (up 230bps).
- FY2024 guidance reaffirmed: revenue $238-242M; gross margin raised to 71%, adjusted EBITDA margin to 21%.
- MACI Arthro launch expected later Q3 2024; NexoBrid pediatric FDA approval anticipated in Q3 2024.
- Net loss $4.7M ($0.10 diluted EPS) vs $5.0M loss in prior year; cash $154M, no debt.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/887359/000162828024033894/0001628280-24-033894-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/887359/000162828024033894/vcel-20240801.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-033894

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer